OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00274254

Chongqing Sansheng Industrial Co Ltd

PharmaceuticalsVerified

Chongqing Sansheng Industrial Co Ltd has a basic and diluted share count of 684,102,041, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare with industry_config preferred metrics or cohort medians. Without these metrics, an assessment of operational efficiency or competitive positioning is not possible at this time. Segment and geographic exposure data are not disclosed in the available source documents, so it is not possible to determine the company's revenue concentration or geographic diversification. Growth trajectory data is also not available in the current dataset, preventing an analysis of the company's revenue history or future outlook. This lack of data limits the ability to assess the company's growth potential or strategic direction. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilutive instruments or recent equity issuance that would affect the share count. Recent events, including filings and transcripts, are not disclosed in the available source documents, so no specific recent developments can be reported.

30-day price · 002742(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyChongqing Sansheng Industrial Co Ltd
Ticker002742.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Chongqing Sansheng Industrial Co Ltd is engaged in the pharmaceuticals industry, producing and selling pharmaceutical products.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

Chongqing Sansheng Industrial Co Ltd has a basic and diluted share count of 684,102,041, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare with industry_config preferred metrics or cohort medians. Without these metrics, an assessment of operational efficiency or competitive positioning is not possible at this time. Segment and geographic exposure data are not disclosed in the available source documents, so it is not possible to determine the company's revenue concentration or geographic diversification. Growth trajectory data is also not available in the current dataset, preventing an analysis of the company's revenue history or future outlook. This lack of data limits the ability to assess the company's growth potential or strategic direction. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilutive instruments or recent equity issuance that would affect the share count. Recent events, including filings and transcripts, are not disclosed in the available source documents, so no specific recent developments can be reported.
Key takeaways
  • The company has no dilution from stock options or convertible securities, as basic and diluted share counts are equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • Profitability and return metrics are not available, limiting the ability to compare with industry benchmarks.
  • Segment and geographic exposure data are not disclosed, making it difficult to assess revenue concentration or diversification.
  • Growth trajectory and recent events are not available in the current dataset, limiting the ability to assess strategic direction or recent developments.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric002742Activity
Op margin18.2% medp25 18.2% · p75 24.6%
Net margin14.7% medp25 11.7% · p75 28.1%
Gross margin19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue4.9% medp25 4.2% · p75 6.3%
Debt / equity71.3% medp25 19.0% · p75 91.7%
Source: analysis-pipeline (hybrid)Generated: 2026-05-20 03:38 UTCJob: 7c2bd651